Advertisement
Screener

ANIXA BIOSCIENCES, INC. (ANIX) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

ANIXA BIOSCIENCES, INC. Share-based Payment Arrangement, Expense

ANIXA BIOSCIENCES, INC. (ANIX) reported Share-based Payment Arrangement, Expense of -$1.11 million for the 3-month period ending 2020-04-30, per its 10-Q filed 2020-06-09.

Discontinued › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2020-06-09

  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2020-04-30 was -$1.11M.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2020-01-31 was $1.02M, a 62.86% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2019-10-31 was -$10.62M.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2019-07-31 was $830.90K, a 82.05% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for fiscal 2019 was -$5.71M.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for fiscal 2018 was -$8.90M.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for fiscal 2017 was -$1.68M.
  • ANIXA BIOSCIENCES, INC. share-based payment arrangement, expense for fiscal 2015 was $2.68M, a 15.03% decline from fiscal 2014.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 3 month as first filedShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 6 month as first filedShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 9 month as first filedShare-based Payment Arrangement, Expense 12 monthShare-based Payment Arrangement, Expense 12 month as first filed
2020-04-30-$1.11M
10-Q · filed 2020-06-09
-$2.13M
10-Q · filed 2020-06-09
-$10.71M
derived: sum of 3 quarters · filed 2020-06-09
-$9.87M
derived: sum of 4 quarters · filed 2020-06-09
2020-01-31$1.02M
10-Q · filed 2020-03-09
-$9.59M
derived: sum of 2 quarters · filed 2020-03-09
-$8.76M
derived: sum of 3 quarters · filed 2020-03-09
-$10.09M
derived: sum of 4 quarters · filed 2020-06-09
2019-10-31-$10.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09
-$9.79M
derived: sum of 2 quarters · filed 2020-01-09
-$11.11M
derived: sum of 3 quarters · filed 2020-06-09
-$5.71M
10-K · filed 2020-01-09
2019-07-31$830.90K
10-Q · filed 2019-09-06
-$490.55K
derived: sum of 2 quarters · filed 2020-06-09
$4.90M
10-Q · filed 2019-09-06
-$11.86M
derived: sum of 4 quarters · filed 2020-06-09
2019-04-30-$1.32M
10-Q · filed 2020-06-09
$1.32M
10-Q · filed 2019-06-12
-$4.07M
10-Q · filed 2020-06-09
$4.07M
10-Q · filed 2019-06-12
-$12.69M
derived: sum of 3 quarters · filed 2020-06-09
-$8.07M
derived: sum of 4 quarters · filed 2020-06-09
2019-01-31$2.75M
10-Q · filed 2020-03-09
-$11.37M
derived: sum of 2 quarters · filed 2020-03-09
-$6.74M
derived: sum of 3 quarters · filed 2020-03-09
-$6.41M
derived: sum of 4 quarters · filed 2020-03-09
2018-10-31-$14.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09
-$9.49M
derived: sum of 2 quarters · filed 2020-01-09
-$9.16M
derived: sum of 3 quarters · filed 2020-01-09
-$8.90M
10-K · filed 2020-01-09
2018-07-31$4.63M
10-Q · filed 2019-09-06
$4.96M
derived: sum of 2 quarters · filed 2019-09-06
$5.23M
10-Q · filed 2019-09-06
2018-04-30$331.71K
10-Q · filed 2019-06-12
$598.68K
10-Q · filed 2019-06-12
2018-01-31$266.97K
10-Q · filed 2019-03-13
2017-10-31-$1.68M
10-K · filed 2019-01-11
2016-07-31$240.44K
10-Q · filed 2016-08-19
$457.69K
derived: sum of 2 quarters · filed 2016-08-19
$570.19K
10-Q · filed 2016-08-19
$908.20K
derived: sum of 4 quarters · filed 2016-08-19
2016-04-30$217.25K
10-Q · filed 2016-05-20
$329.75K
10-Q · filed 2016-05-20
$667.76K
derived: sum of 3 quarters · filed 2016-05-20
$1.45M
derived: sum of 4 quarters · filed 2016-08-19
2016-01-31$112.50K
10-Q · filed 2016-02-19
$450.50K
derived: sum of 2 quarters · filed 2016-02-19
$1.23M
derived: sum of 3 quarters · filed 2016-08-19
$2.30M
derived: sum of 4 quarters · filed 2016-08-19
2015-10-31$338.01K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23
$1.12M
derived: sum of 2 quarters · filed 2016-08-19
$2.18M
derived: sum of 3 quarters · filed 2016-08-19
$2.68M
10-K · filed 2015-12-23
2015-07-31$780.59K
10-Q · filed 2016-08-19
$1.85M
derived: sum of 2 quarters · filed 2016-08-19
$2.34M
10-Q · filed 2016-08-19
$3.14M
derived: sum of 4 quarters · filed 2016-08-19
2015-04-30$1.07M
10-Q · filed 2016-05-20
$1.56M
10-Q · filed 2016-05-20
$2.36M
derived: sum of 3 quarters · filed 2016-05-20
$2.83M
derived: sum of 4 quarters · filed 2016-05-20
2015-01-31$491.78K
10-Q · filed 2016-02-19
$1.29M
derived: sum of 2 quarters · filed 2016-02-19
$1.76M
derived: sum of 3 quarters · filed 2016-02-19
$2.92M
derived: sum of 4 quarters · filed 2016-02-19
2014-10-31$803.21K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23
$1.27M
derived: sum of 2 quarters · filed 2015-12-23
$2.43M
derived: sum of 3 quarters · filed 2015-12-23
$3.15M
10-K · filed 2015-12-23
2014-07-31$469.48K
10-Q · filed 2015-08-18
$1.63M
derived: sum of 2 quarters · filed 2015-08-18
$2.35M
10-Q · filed 2015-08-18
$2.98M
derived: sum of 4 quarters · filed 2015-08-18
2014-04-30$1.16M
10-Q · filed 2015-05-22
$1.88M
10-Q · filed 2015-05-22
$2.51M
derived: sum of 3 quarters · filed 2015-05-22
$3.99M
derived: sum of 4 quarters · filed 2015-05-22
2014-01-31$720.64K
10-Q · filed 2015-03-09
$1.36M
derived: sum of 2 quarters · filed 2015-03-09
$2.83M
derived: sum of 3 quarters · filed 2015-03-09
$3.70M
derived: sum of 4 quarters · filed 2015-03-09
2013-10-31$637.14K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-01-29
$2.11M
derived: sum of 2 quarters · filed 2015-01-29
$2.98M
derived: sum of 3 quarters · filed 2015-01-29
$3.80M
10-K · filed 2015-01-29
$4.07M
10-K/A · filed 2014-01-17
2013-07-31$1.47M
10-Q/A · filed 2013-09-20
$2.34M
derived: sum of 2 quarters · filed 2013-09-20
$3.16M
10-Q/A · filed 2013-09-20
$3.43M
derived: sum of 4 quarters · filed 2014-03-17
2013-04-30$871.00K
10-Q/A · filed 2013-06-19
$1.69M
10-Q/A · filed 2013-06-19
$1.96M
derived: sum of 3 quarters · filed 2014-03-17
$2.55M
derived: sum of 4 quarters · filed 2014-03-17
2013-01-31$26.00K
10-Q · filed 2014-03-17
$819.00K
10-Q/A · filed 2013-03-25
$1.09M
derived: sum of 2 quarters · filed 2014-03-17
$1.68M
derived: sum of 3 quarters · filed 2014-03-17
$2.31M
derived: sum of 4 quarters · filed 2014-03-17
2012-10-31$1.06M
derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2014-01-17
$1.66M
derived: sum of 2 quarters · filed 2014-01-17
$2.29M
derived: sum of 3 quarters · filed 2014-01-17
$3.00M
10-K/A · filed 2014-01-17
2012-07-31$595.00K
10-Q/A · filed 2013-09-20
$0.00
10-Q · filed 2012-09-14
$1.23M
derived: sum of 2 quarters · filed 2013-09-20
$1.94M
10-Q/A · filed 2013-09-20
$111.00K
10-Q · filed 2012-09-14
$4.96M
derived: sum of 4 quarters · filed 2013-09-20
2012-04-30$631.00K
10-Q/A · filed 2013-06-19
$1.34M
10-Q/A · filed 2013-06-19
$4.36M
derived: sum of 3 quarters · filed 2013-06-19
$4.70M
derived: sum of 4 quarters · filed 2013-06-19
2012-01-31$713.00K
10-Q/A · filed 2013-03-25
$3.73M
derived: sum of 2 quarters · filed 2013-03-25
$4.07M
derived: sum of 3 quarters · filed 2013-03-25
2011-10-31$3.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-01-29
$3.35M
derived: sum of 2 quarters · filed 2013-01-29
$3.66M
10-K · filed 2013-01-29
2011-07-31$334.00K
10-Q · filed 2012-09-14
$643.00K
10-Q · filed 2012-09-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ProMIS Neurosciences Inc. (PMN)$0.102B
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92